- High gross margin of 92.4%
- Beat earnings estimates in 3 of the last 4 quarters
- Highly efficient cash conversion (102% FCF/OCF ratio)
Stronger technical forecast for TScan Therapeutics, Inc. stock price after Friday trading
(Updated on Jul 10, 2026)
The TScan Therapeutics, Inc. stock price gained 2.83% on the last trading day (Friday, 10th Jul 2026), rising from $1.06 to $1.09. During the last trading day the stock fluctuated 6.34% from a day low at $1.03 to a day high of $1.09. The price has risen in 7 of the last 10 days and is up by 29.76% over the past 2 weeks. Volume fell on the last day by -295 thousand shares and in total, 969 thousand shares were bought and sold for approximately $1.06 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -17.80% during the next 3 months and, with a 90% probability hold a price between $0.654 and $1.03 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
TCRX Signals & Forecast
The TScan Therapeutics, Inc. stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately $1.09. On a fall, the stock will find some support from the long-term average at approximately $0.99. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, July 08, 2026, and so far it has fallen -13.49%. Further fall is indicated until a new bottom pivot has been found. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Support, Risk & Stop-loss for TScan Therapeutics, Inc. stock
TScan Therapeutics, Inc. finds support from accumulated volume at $1.07 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0650 between high and low, or 6.34%. For the last week the stock has had daily average volatility of 12.95%.
Our recommended stop-loss: $1.03 (-5.30%) (This stock has high daily movements and this gives high risk. There is a sell signal from a pivot top found 2 days ago.)
Trading Expectations (TCRX) For The Upcoming Trading Day Of Monday 13th
For the upcoming trading day on Monday, 13th we expect TScan Therapeutics, Inc. to open at $1.07, and during the day (based on 14 day Average True Range), to move between $1.04 and $1.14, which gives a possible trading interval of +/-$0.0992 (+/-9.53%) up or down from last closing price. If TScan Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 9.53% move between the lowest and the highest trading price during the day.
Since the stock is closer to the support from accumulated volume at $1.07 (1.83%) than the resistance at $1.21 (11.01%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..
Is TScan Therapeutics, Inc. stock A Buy?
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.
Current score:
2.407
Buy Candidate
Upgraded
Predicted Fair Opening Price
Predicted fair opening price on July 13, 2026 - $1.07 ( 1.99%).
Want to trade but not sure how?
Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker* 
*Your capital is at risk
TCRX Performance
Trading levels for TCRX
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 1.13 | 3.98% |
| R2 | 1.11 | 1.70% |
| R1 | 1.09 | 0.290% |
| Price | 1.09 | |
| S1 | 1.04 | -4.27% |
| S2 | 1.03 | -5.67% |
| S3 | 1.00 | -7.95% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 1.26 | 15.60% |
| R2 | 1.25 | 14.68% |
| R1 | 1.21 | 11.01% |
| Price | 1.09 | |
| S1 | 1.07 | -1.83% |
| S2 | 1.06 | -2.75% |
| S3 | 1.02 | -6.42% |
FAQ
Click here for our free guide on how to buy TScan Therapeutics, Inc. Stock.
Buy TCRX